Dear Editor,Hepatocellular carcinoma(HCC)is the second leading cause of cancer-related death worldwide with a 5-year survival rate-50-80% after curative treatment,like surgery,targeted therapy plus TACE or RFA or loca...Dear Editor,Hepatocellular carcinoma(HCC)is the second leading cause of cancer-related death worldwide with a 5-year survival rate-50-80% after curative treatment,like surgery,targeted therapy plus TACE or RFA or local treatments,immunotherapy,and so on.1 The approval of several angiogenesis inhibitors,such as sorafenib,regorafenib,lenvatinib,and cabozantinib,have shown therapeutic potential for HCC treatment.However,the improvement of overall survival or progression-free survival is still limited based on angiogenesis inhibitor monotherapy at present.展开更多
基金This work was supported by the Strategic Priority Research Program of the Chinese Academy of Science(Nos.XDA12020101 and XDA12050101)National Natural Science Foundation of China(81521005).
文摘Dear Editor,Hepatocellular carcinoma(HCC)is the second leading cause of cancer-related death worldwide with a 5-year survival rate-50-80% after curative treatment,like surgery,targeted therapy plus TACE or RFA or local treatments,immunotherapy,and so on.1 The approval of several angiogenesis inhibitors,such as sorafenib,regorafenib,lenvatinib,and cabozantinib,have shown therapeutic potential for HCC treatment.However,the improvement of overall survival or progression-free survival is still limited based on angiogenesis inhibitor monotherapy at present.
